# Texas IMPACT Consortium

**Full name:** Texas Ibogaine Multi-site Program for Addiction and Combat Trauma (IMPACT)

**Location:** Texas

**Total funding:** ~$100 million ($50M state + $50M ARPA-H federal match)

**Focus:** Ibogaine research for addiction and combat-related trauma in veteran populations

## Funding Structure

**State investment:** $50 million from Texas state government

**Federal match:** $50 million from ARPA-H EVIDENT initiative, implementing Trump April 18, 2026 Executive Order matching mechanism

**Total:** ~$100 million—largest single psychedelic research investment to date

## Strategic Context

**Political constituency:** Veteran-focused research transcends partisan politics, enabling conservative state (Texas) to lead psychedelic research investment. Veteran constituency provides political cover for Schedule I substance research.

**Evidence base:** Funding allocated before Phase 3 completion, based primarily on Stanford n=30 pilot study, illustrating constituency-driven acceleration ahead of traditional evidence hierarchy.

**Indication focus:** Opioid use disorder (OUD) and combat-related PTSD in veteran populations

## Timeline

- **2026-04-18** — Trump Executive Order directs ARPA-H to match state psychedelic research investments
- **2026-04-24** — Texas IMPACT consortium funding confirmed: $50M state + $50M ARPA-H federal match

## Analysis

The $100M total funding represents the largest single psychedelic research investment in history, exceeding all prior private pharmaceutical and philanthropic investments in individual psychedelic programs. The funding level—allocated before Phase 3 completion—demonstrates that veteran constituency political priority is overriding traditional evidence hierarchy requirements.

Texas as the lead state is strategically significant: conservative state leadership in psychedelic research signals bipartisan political viability when framed through veteran healthcare rather than counterculture associations.

Ibogaine's cardiac safety concerns (QT prolongation, arrhythmia risk) remain the primary regulatory barrier. The IMPACT consortium funding likely includes cardiac safety protocol development (IV magnesium co-administration, continuous monitoring) to address FDA approval pathway requirements.